Rankings
▼
Calendar
BMRN
BioMarin Pharmaceutical Inc.
$12B
Q1 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$596M
+14.8% YoY
Gross Profit
$461M
77.3% margin
Operating Income
$62M
10.5% margin
Net Income
$51M
8.5% margin
EPS (Diluted)
$0.26
QoQ Revenue Growth
+11.0%
Cash Flow
Operating Cash Flow
-$74M
Free Cash Flow
-$99M
Stock-Based Comp.
$54M
Balance Sheet
Total Assets
$6.4B
Total Liabilities
$1.8B
Stockholders' Equity
$4.7B
Cash & Equivalents
$580M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$596M
$519M
+14.8%
Gross Profit
$461M
$402M
+14.6%
Operating Income
$62M
$137M
-54.6%
Net Income
$51M
$121M
-57.9%
Revenue Segments
Product
$586M
56%
Enzyme Product
$448M
43%
Royalty And Other
$10M
1%
← FY 2023
All Quarters
Q2 2023 →
BMRN Q1 2023 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena